Oral Weight Loss Drugs Ranked and Compared | Harbor

The weight loss medication landscape has shifted dramatically. Injectable GLP-1 drugs like Wegovy and Zepbound dominate headlines, but millions of patients still prefer or medically require an oral option. Whether it's needle aversion, cost constraints, or a physician's clinical judgment, pills remain a cornerstone of pharmacological obesity treatment.

Yet choosing among FDA-approved oral weight-loss drugs isn't straightforward. Efficacy varies by a factor of three across available options. Side effect profiles diverge sharply. And the cost, particularly for the uninsured, can range from under $60 per month to over $800 per month. A 2024 systematic review and network meta-analysis published in The Lancet examined randomized controlled trials across all major anti-obesity pharmacotherapies and ranked phentermine-topiramate and GLP-1 receptor agonists as the most effective drugs for reducing body weight. That finding frames the core question this post sets out to answer: where does each oral medication actually land when you stack efficacy, safety, tolerability, and cost side by side?

What follows is a clinical-evidence-based ranking of every major FDA-approved oral weight loss drug available today, built from peer-reviewed meta-analyses, phase 3 trial data, and real-world prescribing considerations. No marketing fluff, just the data and the practical context you need to have an informed conversation with your provider.

taking oral weight loss medication tablet on tongue

Why Oral Weight Loss Drugs Still Matter in the Age of Injectables

It's tempting to dismiss oral anti-obesity medications as relics of a pre-GLP-1 era. That would be a mistake.

The FDA approved oral semaglutide (Wegovy pill) for chronic weight management in December 2025, marking the first oral GLP-1 therapy cleared specifically for obesity. But even with this milestone, the older generation of oral weight loss drugs, phentermine-topiramate, naltrexone-bupropion, and orlistat continues to serve a massive patient population. According to the Obesity Medicine Association, these medications remain first-line options for many clinicians, particularly when GLP-1 agents are contraindicated, unaffordable, or unavailable.

There are practical reasons for their staying power. Generic phentermine-topiramate launched in the U.S. in May 2025, dramatically lowering costs. Orlistat's over-the-counter formulation (Alli) requires no prescription at all. And naltrexone-bupropion (Contrave) addresses a specific clinical niche, patients whose eating behavior is driven by cravings and reward-seeking rather than hunger alone.

For patients exploring their options, platforms like Harbor are making it easier to navigate the increasingly complex weight management landscape, connecting individuals with evidence-based treatment pathways and clinical guidance tailored to their specific needs.

The point is simple: injectable GLP-1s are powerful, but they aren't the only path. Understanding how oral options compare and where each one excels gives patients and providers a fuller toolkit.

How We Ranked: Methodology Behind the Comparison

Rankings without transparent criteria are just opinions. Here's exactly what this comparison evaluates, and where the data comes from.

Efficacy

The primary measure is the mean percentage of body weight lost versus placebo at 12 months (or the nearest available endpoint), drawn from phase 3 randomized controlled trials and confirmed by network meta-analyses. We also consider the proportion of patients achieving clinically meaningful thresholds: 5%, 10%, and 15% total body weight loss.

Safety and Tolerability

Side effect profiles are assessed using discontinuation rates due to adverse events from pooled clinical trial data, the presence of black box warnings, and any outstanding FDA postmarketing safety requirements.

Cost and Accessibility

We compare retail pricing without insurance, availability of generics, manufacturer savings programs, and over-the-counter access where applicable.

Evidence Base

Drugs with larger bodies of long-term data and replication across multiple trials receive higher confidence in their ranking position. A single strong trial is less convincing than consistent results across five.

The primary sources informing this ranking include the 2024 Lancet network meta-analysis of anti-obesity pharmacotherapies, individual phase 3 trial publications in The New England Journal of Medicine and The Lancet, and meta-analyses published in Nature Medicine and eClinicalMedicine.

Tier 1: Phentermine-Topiramate, The Strongest Legacy Oral Drug

Brand name: Qsymia FDA approval: 2012

Mechanism: Sympathomimetic amine (appetite suppressant) combined with an anticonvulsant that enhances satiety

Available doses: 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, 15/92 mg

Efficacy Data

Phentermine-topiramate consistently produces the highest weight loss among non-GLP-1 oral medications, and it isn't close. A systematic review and meta-analysis published in Pharmaceuticals found that the combination produced an average placebo-subtracted weight loss of 7.73 kg across all doses. Broken down by strength: the low dose (3.75/23 mg) yielded 3.55 kg of additional weight loss, the mid dose (7.5/46 mg) produced 7.27 kg, and the top dose (15/92 mg) reached 8.25 kg beyond placebo.

In practical terms, that top dose translates to roughly 8.9% placebo-subtracted body weight loss, a figure confirmed by the 2024 Lancet network meta-analysis, which positioned phentermine-topiramate alongside GLP-1 receptor agonists as the most effective pharmacotherapies for weight reduction.

The threshold data is equally striking. In the CONQUER and EQUIP trials published in The Lancet and Obesity, approximately 75% of patients on the top dose achieved at least 5% body weight loss, compared to roughly 30% on placebo. Nearly half reached the 10% threshold.

Safety Profile

The combination is not without trade-offs. Topiramate carries teratogenic risk (FDA Pregnancy Category X), making effective contraception mandatory for women of childbearing potential. Common side effects include paresthesia (tingling in the extremities), dry mouth, constipation, insomnia, and dysgeusia (altered taste). Cognitive effects often described as "brain fog" are a known topiramate side effect, though they tend to be dose-dependent and often resolve with continued use.

The cardiovascular picture is nuanced. Clinical trials showed dose-dependent increases in heart rate, prompting the FDA to require postmarketing cardiovascular outcomes evaluation. However, a study published in The Journal of Clinical Endocrinology & Metabolism found no increased risk of arrhythmias, valve disease, or myocardial infarction during or after treatment, though the study excluded patients with pre-existing cardiac conditions.

Discontinuation rates due to adverse events were moderate (OR = 2.40 vs. placebo), lower than naltrexone-bupropion but higher than orlistat.

Cost

Brand-name Qsymia retails at approximately $257–$311 for a 30-day supply without insurance. However, the landscape shifted meaningfully when the first generic phentermine-topiramate ER was launched in May 2025. With manufacturer savings cards, self-pay patients can access the medication for under $100 per month, and some home delivery pharmacy programs offer 30-day prescriptions for $89.

For patients who tolerate it, phentermine-topiramate delivers the most weight loss of any non-GLP-1 oral drug by a significant margin. The generic launch has removed much of the cost barrier that previously limited access.

Tier 2: Oral Semaglutide The New GLP-1 Pill

Brand name: Wegovy (oral), Rybelsus (for diabetes, not obesity-indicated)

FDA approval for obesity: December 2025

Mechanism: GLP-1 receptor agonist mimics a gut hormone that regulates appetite and satiety

Dose: 25 mg once daily (titrated from 1.5 mg)

oral weight loss pills and capsules with measuring tape

Efficacy Data

Oral semaglutide represents a genuine breakthrough for patients who want GLP-1-level weight loss without injections. The OASIS 4 trial, involving 307 adults with obesity or overweight, demonstrated a mean weight loss of 13.6% at 64 weeks versus placebo. Larger studies with higher doses showed even more impressive numbers up to 16.6% average body weight loss, with one in three participants losing 20% or more.

These figures place oral semaglutide well above all older oral options and close to the efficacy of its injectable counterpart (which produces roughly 15–16% weight loss in clinical trials).

Safety Profile

The side effect profile mirrors injectable semaglutide: predominantly gastrointestinal. Nausea, vomiting, diarrhea, and constipation are the most common adverse events and are typically most pronounced during dose titration. The slow escalation from 1.5 mg to 25 mg over several months is designed to mitigate these effects.

Important practical constraints: oral semaglutide must be taken on an empty stomach with no more than 4 ounces of plain water, and patients must wait at least 30 minutes before eating, drinking, or taking other oral medications. This dosing requirement can be a real barrier to adherence.

Cost

Novo Nordisk has priced oral Wegovy at $149 per month for the two lowest titration doses and $299 per month at maintenance doses for cash-pay patients. This is meaningfully cheaper than injectable Wegovy ($199–$499/month through manufacturer programs) and represents a significant step toward broader GLP-1 access.

Oral semaglutide is now the most effective oral weight loss drug available, full stop. Its placement in Tier 2 rather than Tier 1 reflects only that it launched in early 2026 and doesn't yet have the long-term real-world data that phentermine-topiramate has accumulated over a decade. For raw efficacy, it wins.

Tier 3: Naltrexone-Bupropion The Craving-Focused Option

Brand name: Contrave

FDA approval: 2014

Mechanism: Opioid antagonist (naltrexone) combined with a norepinephrine-dopamine reuptake inhibitor (bupropion) targets the brain's reward and hunger pathways

Dose: Up to 2 tablets twice daily (each tablet: 8 mg naltrexone / 90 mg bupropion ER)

Efficacy Data

Contrave's weight loss performance is moderate. Pooled results from four phase 3 trials (the COR trial program) show a placebo-subtracted mean weight loss of 4.7% at one year, with individual trials ranging from 3.2% to 5.2%. Approximately 55% of patients achieved the 5% body weight loss threshold, compared to about 30% on placebo.

These numbers place naltrexone-bupropion clearly below phentermine-topiramate (which nearly doubles its efficacy) and well below oral semaglutide. However, the drug's mechanism of action addresses something the others don't as directly: the psychological and reward-driven components of overeating.

A 2022 analysis published in eClinicalMedicine (part of The Lancet family) found that early weight loss response at 16 weeks was a strong predictor of long-term success with Contrave, suggesting that clinicians can identify likely responders relatively quickly and discontinue in non-responders a useful clinical advantage.

Safety Profile

Contrave carries a black box warning for suicidal thoughts and behavior associated with bupropion, the antidepressant component. This warning applies broadly to all bupropion-containing products and requires clinicians to monitor patients for neuropsychiatric symptoms, particularly during the first few months.

Common side effects include nausea (the most frequent reason for discontinuation), constipation, headache, vomiting, and dizziness. The discontinuation rate due to adverse events is the highest among the three legacy oral drugs (OR = 2.69 vs. placebo).

Contrave is contraindicated in patients with uncontrolled hypertension, seizure disorders, eating disorders (bulimia or anorexia nervosa), and those undergoing abrupt opioid discontinuation.

Cost

Contrave's cost story has improved but remains complex. The retail price without insurance exceeds $800 per month at full dose (120 tablets). However, the manufacturer partnered with Ridgeway Mail Order Pharmacy to offer a $99 per month program. Through GoodRx, cash-paying patients can access Contrave for approximately $199 per month. Commercially insured patients with coverage may pay as little as $20 per 30-day supply.

Contrave occupies a specific clinical niche: patients whose weight gain is driven by cravings, emotional eating, or reward-seeking behavior. For that population, its dual mechanism makes pharmacological sense. For everyone else, phentermine-topiramate and oral semaglutide deliver substantially more weight loss.

Tier 4: Orlistat, The Oldest and Most Modest Option

Brand name: Xenical (prescription, 120 mg), Alli (OTC, 60 mg)

FDA approval: 1999 (Xenical), 2007 (Alli OTC)

Mechanism: Pancreatic lipase inhibitor blocks approximately 30% of dietary fat absorption in the gut.

Dose: 120 mg three times daily with meals (prescription) or 60 mg three times daily (OTC)

Efficacy Data

Orlistat is the weakest performer in this ranking by a clear margin. The 2024 Lancet network meta-analysis and multiple earlier systematic reviews consistently show a placebo-subtracted weight loss of approximately 2.9% at one year. In the Institute for Clinical and Economic Review's (ICER) comparative assessment, only 44% of orlistat patients achieved the 5% body weight loss threshold, compared to 75% on phentermine-topiramate and 55% on naltrexone-bupropion.

That said, orlistat does have one of the longest safety track records of any weight loss medication, with over two decades of post-market data and more than 22 randomized controlled trials included in major meta-analyses.

Safety Profile

Orlistat's side effects are unique among this class; they're almost entirely gastrointestinal and directly tied to its mechanism. When patients consume dietary fat, the unabsorbed fat must go somewhere. That means oily spotting, flatulence with discharge, fecal urgency, fatty or oily stools, and increased defecation. These effects are manageable on a low-fat diet but can be socially and practically distressing.

On the positive side, orlistat has the lowest discontinuation rate due to adverse events among all oral anti-obesity drugs (OR = 1.72 vs. placebo) and carries no cardiovascular concerns. It can also modestly reduce LDL cholesterol independent of weight loss, due to reduced fat absorption.

Rare but serious hepatic adverse events have been reported post-market, though a causal link has not been definitively established.

Cost

Orlistat has the most accessible pricing structure in this entire category. The over-the-counter Alli formulation (60 mg) costs approximately $53–$70 for a 120-capsule supply at major retailers like Walmart and Costco, roughly $0.50–$0.60 per dose. Prescription-strength Xenical (120 mg) is significantly more expensive at retail ($638–$880 for 90 capsules), but the OTC option means patients can begin treatment without a prescription or doctor visit.

Orlistat is the least effective oral weight loss drug by a wide margin. Its primary advantages are an unmatched safety record, no prescription requirement (at OTC doses), and the lowest cost of any option. It's a reasonable choice for patients seeking modest support alongside dietary changes, but expectations should be calibrated accordingly.

The Emerging Oral Pipeline: What's Coming Next

The oral weight loss drug landscape is about to get much more competitive. Two pipeline drugs deserve attention.

Orforglipron (Eli Lilly)

Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist with fundamentally different chemistry from oral semaglutide. Because it's not a peptide, it's more stable in the stomach and can be taken with food, eliminating the restrictive dosing requirements of oral semaglutide.

Phase 3 trial results published in The New England Journal of Medicine showed 11.2% body weight loss at the 36 mg dose over 72 weeks. The FDA is reviewing Eli Lilly's submission, with a decision expected by April 10, 2026.

If approved, orforglipron could reshape the oral GLP-1 market by offering a more patient-friendly dosing experience. Taking a pill with breakfast is a radically different proposition from taking one on an empty stomach with restricted water and a 30-minute fasting window.

Aleniglipron (Structure Therapeutics)

Phase 2 data from the ACCESS and ACCESS II trials showed 11–15% body weight loss at 36 weeks, and that's a phase 2 result over a shorter timeframe. If these numbers hold or improve in phase 3, aleniglipron could emerge as a serious competitor.

The pharmaceutical analytics platform Ozmosi predicts one to two new GLP-1 launches annually starting in 2026, with 39 GLP-1 receptor agonist-related medications currently in development as of mid-2025. The oral weight loss drug category is about to go from a handful of options to a crowded, competitive field.

Head-to-Head Comparison: Picking the Right Drug for the Right Patient

Reducing this to a simple "best to worst" list misses the clinical reality. Different drugs suit different patients. Here's how to think about the decision.

When Phentermine-Topiramate Makes Sense

This is the strongest choice for patients who want maximum weight loss from an established, affordable oral medication and can tolerate central nervous system side effects. It's particularly relevant for patients with comorbid migraines (topiramate is independently FDA-approved for migraine prevention) or those who have tried and failed other options. It is not appropriate for women planning pregnancy or those with uncontrolled cardiovascular disease.

When Oral Semaglutide Makes Sense

For patients who want the efficacy of a GLP-1 drug without injections and can adhere to the fasting dosing protocol, this is the clear front-runner. It's especially relevant for patients with type 2 diabetes as a comorbidity, given semaglutide's robust glycemic benefits. Cost remains a barrier for uninsured patients, though less so than injectable GLP-1s.

When Contrave Makes Sense

Contrave's sweet spot is patients whose overeating is driven by cravings, food preoccupation, or reward-seeking behavior, particularly if they also have mild-to-moderate depression (bupropion has antidepressant properties). It's a poor choice for patients with seizure disorders, eating disorders, or those taking opioid medications.

When Orlistat Makes Sense

Orlistat is best suited to patients seeking a modest, low-risk intervention alongside dietary changes. It's the only option available over the counter, making it the most accessible entry point for someone not yet ready for prescription treatment. Its mechanism also makes it a reasonable add-on therapy alongside appetite-suppressing drugs, though combination data is limited.

What the Data Tells Us and What It Doesn't

The clinical trial evidence is clear on the efficacy hierarchy: oral semaglutide leads, phentermine-topiramate follows, naltrexone-bupropion is moderate, and orlistat trails. But clinical trials operate in controlled environments with motivated participants, regular follow-up, and structured support.

Real-world effectiveness depends on factors that trials don't fully capture: whether a patient can afford the monthly refill, whether side effects are tolerable over years rather than months, whether the dosing protocol fits into a daily routine, and whether the prescribing clinician monitors and adjusts treatment appropriately.

woman showing oral weight loss drug results in oversized jeans

Long-term data also remains a gap for the newest entry. Oral semaglutide was approved for obesity only in December 2025, so we have robust trial data but limited post-market experience. Phentermine-topiramate, by contrast, has over a decade of real-world use, though its FDA-required cardiovascular outcomes study still hasn't delivered definitive results.

What the data does tell us is that pharmacotherapy works best as one component of a comprehensive approach. The medications that perform best in trials do so alongside dietary counseling, behavioral support, and physical activity guidance. A drug alone is a tool. A drug within a structured treatment plan is a strategy.

For anyone evaluating which oral weight loss medication fits their situation, the next step isn't choosing a pill; it's having a detailed conversation with a qualified clinician who can weigh your medical history, comorbidities, and goals against the evidence. The data in this post gives you the foundation to make that conversation a productive one.

Sources: